Yarrow Bioscience, Inc. (YARW)
13.56
-0.67
(-4.71%)
USD |
NASDAQ |
Nov 20, 12:23
Yarrow Bioscience Cash from Investing (Quarterly) : -5.00M for Sept. 30, 2026
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | -5.00M |
| June 30, 2026 | 0.30M |
| March 31, 2026 | 4.70M |
| December 31, 2025 | 8.46M |
| September 30, 2025 | 4.402M |
| June 30, 2025 | 4.675M |
| March 31, 2025 | 19.83M |
| December 31, 2024 | 12.74M |
| September 30, 2024 | -4.824M |
| June 30, 2024 | 19.02M |
| March 31, 2024 | -3.569M |
| December 31, 2023 | -62.35M |
| September 30, 2023 | 0.00 |
| June 30, 2023 | 0.00 |
| March 31, 2023 | 5.00M |
| December 31, 2022 | -0.935M |
| September 30, 2022 | -0.086M |
| June 30, 2022 | 0.00 |
| March 31, 2022 | 16.69M |
| December 31, 2021 | 0.00 |
| Date | Value |
|---|---|
| September 30, 2021 | 0.00 |
| June 30, 2021 | 1.027M |
| March 31, 2021 | 0.00 |
| December 31, 2020 | 2.002M |
| September 30, 2020 | 0.00 |
| June 30, 2020 | 21.12M |
| March 31, 2020 | 65.98M |
| December 31, 2019 | 6.034M |
| September 30, 2019 | -4.677M |
| June 30, 2019 | 32.77M |
| March 31, 2019 | 7.739M |
| December 31, 2018 | -4.071M |
| September 30, 2018 | 8.296M |
| June 30, 2018 | 7.677M |
| March 31, 2018 | -45.78M |
| December 31, 2017 | 6.311M |
| September 30, 2017 | -36.31M |
| June 30, 2017 | 7.349M |
| March 31, 2017 | 7.587M |
| December 31, 2016 | 1.156M |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Cypherpunk Technologies, Inc. | -6.00M |
| Cue Biopharma, Inc. | 0.00 |
| Faeth Therapeutics, Inc. | 0.175M |
| Indaptus Therapeutics, Inc. | 0.0882M |
| Pyxis Oncology, Inc. | -37.29M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -89.96M |
| Cash from Financing (Quarterly) | 265.03M |
| Free Cash Flow | -99.79M |
| Free Cash Flow Per Share (Quarterly) | -3.982 |
| Free Cash Flow to Equity (Quarterly) | -89.96M |
| Free Cash Flow to Firm (Quarterly) | -89.96M |
| Free Cash Flow Yield | -64.14% |